144 related articles for article (PubMed ID: 19928862)
1. Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Decker M; Si YG; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2010 Jan; 53(1):402-18. PubMed ID: 19928862
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
3. High-affinity carbamate analogues of morphinan at opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1508-11. PubMed ID: 17276685
[TBL] [Abstract][Full Text] [Related]
4. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
[TBL] [Abstract][Full Text] [Related]
5. Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
Decker M; Fulton BS; Zhang B; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2009 Dec; 52(23):7389-96. PubMed ID: 19634902
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
Zhang B; Zhang T; Sromek AW; Scrimale T; Bidlack JM; Neumeyer JL
Bioorg Med Chem; 2011 May; 19(9):2808-16. PubMed ID: 21482470
[TBL] [Abstract][Full Text] [Related]
8. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
Neumeyer JL; Gu XH; van Vliet LA; DeNunzio NJ; Rusovici DE; Cohen DJ; Negus SS; Mello NK; Bidlack JM
Bioorg Med Chem Lett; 2001 Oct; 11(20):2735-40. PubMed ID: 11591513
[TBL] [Abstract][Full Text] [Related]
9. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
[TBL] [Abstract][Full Text] [Related]
10. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
Zhang A; Xiong W; Bidlack JM; Hilbert JE; Knapp BI; Wentland MP; Neumeyer JL
J Med Chem; 2004 Jan; 47(1):165-74. PubMed ID: 14695830
[TBL] [Abstract][Full Text] [Related]
11. In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
Bioorg Med Chem; 2007 Jun; 15(12):4106-12. PubMed ID: 17433695
[TBL] [Abstract][Full Text] [Related]
12. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.
Fulton BS; Knapp BL; Bidlack JM; Neumeyer JL
Bioorg Med Chem Lett; 2010 Mar; 20(5):1507-9. PubMed ID: 20144870
[TBL] [Abstract][Full Text] [Related]
13. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.
Neumeyer JL; Peng X; Knapp BI; Bidlack JM; Lazarus LH; Salvadori S; Trapella C; Balboni G
J Med Chem; 2006 Sep; 49(18):5640-3. PubMed ID: 16942040
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
[TBL] [Abstract][Full Text] [Related]
15. Probes for narcotic receptor mediated phenomena. 43. Synthesis of the ortho-a and para-a, and improved synthesis and optical resolution of the ortho-b and para-b oxide-bridged phenylmorphans: compounds with moderate to low opioid-receptor affinity.
Li F; Folk JE; Cheng K; Kurimura M; Deck JA; Deschamps JR; Rothman RB; Dersch CM; Jacobson AE; Rice KC
Bioorg Med Chem; 2011 Jul; 19(14):4330-7. PubMed ID: 21684752
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
Provencher BA; Sromek AW; Li W; Russell S; Chartoff E; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2013 Nov; 56(21):8872-8. PubMed ID: 24107104
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
[TBL] [Abstract][Full Text] [Related]
20. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
